Heron Therapeutics (HRTX) Work In Process (2016 - 2026)

Heron Therapeutics (HRTX) has reported Work In Process for 11 consecutive years, with $24.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Work In Process fell 7.15% year-over-year to $24.3 million; the trailing twelve-month figure through Jun 2026 stood at $24.3 million (down 7.15% YoY), and the FY2025 full-year result was $26.6 million, down 2.12% from the prior year.
• Work In Process grew to $24.3 million in Q2 2026 per HRTX's latest filing, from $21.6 million in the prior quarter.
• Across five years, Work In Process topped out at $29.0 million in Q1 2025 and bottomed at $9.0 million in Q2 2023.
• Historically, Work In Process has averaged $19.7 million across 5 years, with a median of $19.2 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Work In Process plunged 55.18% in 2023, then jumped 86.87% in 2024.
• Over 5 years, Work In Process stood at $20.7 million in 2022, then dropped by 29.79% to $14.6 million in 2023, then surged by 86.87% to $27.2 million in 2024, then declined by 2.12% to $26.6 million in 2025, then fell by 8.79% to $24.3 million in 2026.
• According to Business Quant data, Work In Process over the past three periods registered $24.3 million, $21.6 million, and $26.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.